Evidence map›Paper›PMID 22326217›Full record

ArticleCell metabolism2012

Challenges and opportunities of defining clinical leptin resistance.

Martin G Myers, Steven B Heymsfield, Carol Haft, Barbara B Kahn, Maren Laughlin, Rudolph L Leibel, Matthias H Tschöp, Jack A Yanovski

Abstract read
In one paragraph

Article in Cell metabolism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Leveraging Multiomic Signatures to Predict Body Composition.Advances in nutrition (Bethesda, Md.) · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. History and future of leptin: Discovery, regulation and signaling.Metabolism: clinical and experimental · 2024
    Review
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Martin G MyersDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI 48105, USA. mgmyers@umich.edu
Steven B Heymsfield
Carol Haft
Barbara B Kahn
Maren Laughlin
Rudolph L Leibel
Matthias H Tschöp
Jack A Yanovski

Funding

Physiology, Psychology, and Genetics of ObesityZIAHD000641 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI YANOVSKI, JACK A. · 2009 to 2025
$24.8M
Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Mechanisms of Leptin Receptors Signal AttenuationR01DK057768 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MYERS, MARTIN G, SIMERLY, RICHARD B · 2000 to 2012
$5.3M
Glucose Transporter Regulation in Obesity and DiabetesR37DK043051 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KAHN, BARBARA B. · 2006 to 2015
$5.0M
Molecular Mechanisms of Leptin Receptor/Jak2 ActionR37DK056731 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MYERS, MARTIN G · 2008 to 2017
$3.5M
Leptin in Human Energy and Neuroendocrine HomeostasisR01DK064773 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LEIBEL, RUDOLPH L · 2003 to 2013
$3.3M
Intramural NIH HHS Z99 DA999999Intramural NIH HHS Z99 HD999999Intramural NIH HHS Z99 HL999999Intramural NIH HHS Z99 MH999999Intramural NIH HHS Z99 OD999999Intramural NIH HHS ZIA HD000641NIDDK NIH HHS P30 DK020572NIDDK NIH HHS R01 DK057768NIDDK NIH HHS R01 DK064773NIDDK NIH HHS R37 DK043051NIDDK NIH HHS R37 DK056731
6 · The paper itself

Abstract

The widespread use of the inadequately defined term "leptin resistance" led the National Institutes of Health to convene a workshop aimed at developing a quantitative definition of this term that would facilitate mechanistic research into leptin's actions in human health and disease. Although leptin-responsive conditions are recognized, the field is limited by a lack of robust, easily quantifiable behavioral or metabolic biomarkers of the hormone's action. Further advances require biomarkers that can be used to identify patients who may benefit from leptin therapy and that are useful for understanding the determinants of clinical leptin responsiveness.

Indexed as

Consensus Development Conferences, NIH as TopicDrug ResistanceHumansLeptinNational Institutes of Health (U.S.)ObesityUnited StatesLeptin

Identifiers

PMID22326217
PMCPMC3281561

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.